![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PHARMACOKINETICS OF PARITAPREVIR, OMBITASVIR, DASABUVIR, RITONAVIR AND RIBAVIRIN IN SUBJECTS WITH HCV GENOTYPE 1 INFECTION IN PHASE 3 STUDIES
|
|
|
EASL: Abbvie at EASL 2015 - Healthcare Economics, Clinical Trials - (05/11/15)
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Sven Mensing Germany et al
![EASL1.gif](../images/051815/051815-3/EASL1.gif)
![EASL2.gif](../images/051815/051815-3/EASL2.gif)
![EASL3.gif](../images/051815/051815-3/EASL3.gif)
![EASL4.gif](../images/051815/051815-3/EASL4.gif)
![EASL5.gif](../images/051815/051815-3/EASL5.gif)
![EASL6.gif](../images/051815/051815-3/EASL6.gif)
![EASL7.gif](../images/051815/051815-3/EASL7.gif)
![EASL8.gif](../images/051815/051815-3/EASL8.gif)
![EASL9.gif](../images/051815/051815-3/EASL9.gif)
![EASL10.gif](../images/051815/051815-3/EASL10.gif)
![EASL11.gif](../images/051815/051815-3/EASL11.gif)
![EASL12.gif](../images/051815/051815-3/EASL12.gif)
![EASL13.gif](../images/051815/051815-3/EASL13.gif)
![EASL14.gif](../images/051815/051815-3/EASL14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|